These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.
    Author: Boutilier AJ, Huang L, Elsawa SF.
    Journal: Int J Mol Sci; 2022 Sep 22; 23(19):. PubMed ID: 36232447.
    Abstract:
    Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
    [Abstract] [Full Text] [Related] [New Search]